UBE2C Induces Cisplatin Resistance via ZEB1/2-Dependent Upregulation of ABCG2 and ERCC1 in NSCLC Cells

OBJECTIVES: Cisplatin (DDP) is one of the most commonly used chemotherapeutic drugs for several cancers, including non-small-cell lung cancer (NSCLC). However, resistance to DDP eventually develops, limiting its further application. New therapy targets are urgently needed to reverse DDP resistance....

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Yan, Jin, Dan, Wang, Xiaohong, Du, Jing, Di, Weihua, An, Jiajia, Shao, Cuijie, Guo, Jiwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6333017/
https://www.ncbi.nlm.nih.gov/pubmed/30693031
http://dx.doi.org/10.1155/2019/8607859

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6333017/
https://www.ncbi.nlm.nih.gov/pubmed/30693031
http://dx.doi.org/10.1155/2019/8607859

Ejemplares similares